Literature DB >> 7693598

Monoclonal immunoglobulin A antibodies directed against cholera toxin prevent the toxin-induced chloride secretory response and block toxin binding to intestinal epithelial cells in vitro.

F M Apter1, W I Lencer, R A Finkelstein, J J Mekalanos, M R Neutra.   

Abstract

Secretory immunoglobulin A (IgA) antibodies directed against cholera toxin (CT) are thought to be important in resistance to oral challenge with virulent Vibrio cholerae, although alternative mechanisms for protection of intestinal epithelia against CT-induced fluid secretion have been proposed. The ability of anti-CT IgA to block the effects of CT on human enterocytes has not been directly tested because of the lack of a well-defined in vitro intestinal epithelial cell system to directly measure toxin action and the limited availability of purified anti-CT IgA antibodies. We have generated hybridomas that produce monoclonal IgA and IgG antibodies directed against CT by fusion of Peyer's patch cells with mouse myeloma cells after oral-systemic immunization of mice with CT and CT B-subunit protein. All of the anti-CT antibodies recognized the B subunit. Three clones (designated anti-CTB IgA-1, IgA-2, and IgA-3) which produced IgA antibodies in dimeric and polymeric forms were selected. Checkerboard immunoblotting demonstrated that IgA-1 recognized an epitope distinct from that recognized by IgA-2 and IgA-3 and that none of the antibodies were directed against the binding site of GM1, the intestinal cell membrane toxin receptor. The protective capacity of these IgAs was tested in vitro with human T84 colon carcinoma cells grown on permeable supports as confluent monolayers of polarized enterocytes. When each anti-CTB IgA was mixed with 10 nM CT and applied to the apical surfaces of T84 cell monolayers, all three IgAs blocked CT-induced Cl- secretion in a dose-dependent manner and completely inhibited binding of rhodamine-labelled CT to apical cell membranes. Thus, monoclonal anti-CTB IgA antibodies are sufficient to protect human enterocytes in vitro against CT binding and action.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693598      PMCID: PMC281311          DOI: 10.1128/iai.61.12.5271-5278.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Established intestinal cell lines as model systems for electrolyte transport studies.

Authors:  K Dharmsathaphorn; J L Madara
Journal:  Methods Enzymol       Date:  1990       Impact factor: 1.600

2.  ADP-ribosylation of membrane proteins catalyzed by cholera toxin: basis of the activation of adenylate cyclase.

Authors:  D M Gill; R Meren
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

3.  Genetic evidence that cholera toxin substrates are regulatory components of adenylate cyclase.

Authors:  G L Johnson; H R Kaslow; H R Bourne
Journal:  J Biol Chem       Date:  1978-10-25       Impact factor: 5.157

4.  Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine.

Authors:  R A Cash; S I Music; J P Libonati; J P Craig; N F Pierce; R B Hornick
Journal:  J Infect Dis       Date:  1974-10       Impact factor: 5.226

5.  Gangliosides and membrane receptors for cholera toxin.

Authors:  P Cuatrecasas
Journal:  Biochemistry       Date:  1973-08-28       Impact factor: 3.162

Review 6.  Pathogenesis of intestinal infections.

Authors:  H Sprinz
Journal:  Arch Pathol       Date:  1969-06

Review 7.  Mechanisms of disease and immunity in cholera: a review.

Authors:  J Holmgren; A M Svennerholm
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

8.  Immunological control mechanism against cholera toxin: interference with toxin binding to intestinal receptors.

Authors:  A L Wu; W A Walker
Journal:  Infect Immun       Date:  1976-10       Impact factor: 3.441

9.  Interaction of cholera toxin and membrane GM1 ganglioside of small intestine.

Authors:  J Holmgren; I Lönnroth; J Månsson; L Svennerholm
Journal:  Proc Natl Acad Sci U S A       Date:  1975-07       Impact factor: 11.205

10.  Mechanism of action of choleragen. Evidence for ADP-ribosyltransferase activity with arginine as an acceptor.

Authors:  J Moss; M Vaughan
Journal:  J Biol Chem       Date:  1977-04-10       Impact factor: 5.157

View more
  33 in total

Review 1.  Secretory IgA: arresting microbial pathogens at epithelial borders.

Authors:  Nicholas J Mantis; Stephen J Forbes
Journal:  Immunol Invest       Date:  2010       Impact factor: 3.657

2.  Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization.

Authors:  Curtis P Bradney; Gregory D Sempowski; Hua-Xin Liao; Barton F Haynes; Herman F Staats
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  TTSS2-deficient hha mutant of Salmonella Typhimurium exhibits significant systemic attenuation in immunocompromised hosts.

Authors:  Vikalp Vishwakarma; Niladri Bhusan Pati; Shilpa Ray; Susmita Das; Mrutyunjay Suar
Journal:  Virulence       Date:  2014-01-08       Impact factor: 5.882

Review 4.  Resident Memory B Cells.

Authors:  S Rameeza Allie; Troy D Randall
Journal:  Viral Immunol       Date:  2020-02-05       Impact factor: 2.257

Review 5.  Pathogenesis of human enterovirulent bacteria: lessons from cultured, fully differentiated human colon cancer cell lines.

Authors:  Vanessa Liévin-Le Moal; Alain L Servin
Journal:  Microbiol Mol Biol Rev       Date:  2013-09       Impact factor: 11.056

6.  Immune exclusion by naturally acquired secretory IgA against pneumococcal pilus-1.

Authors:  Ulrike Binsker; John A Lees; Alexandria J Hammond; Jeffrey N Weiser
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

7.  Vaccine-induced intestinal immunity to ricin toxin in the absence of secretory IgA.

Authors:  Lori M Neal; Elizabeth A McCarthy; Carolyn R Morris; Nicholas J Mantis
Journal:  Vaccine       Date:  2010-11-27       Impact factor: 3.641

8.  Analysis of the roles of antilipopolysaccharide and anti-cholera toxin immunoglobulin A (IgA) antibodies in protection against Vibrio cholerae and cholera toxin by use of monoclonal IgA antibodies in vivo.

Authors:  F M Apter; P Michetti; L S Winner; J A Mack; J J Mekalanos; M R Neutra
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

9.  A monoclonal immunoglobulin G antibody directed against an immunodominant linear epitope on the ricin A chain confers systemic and mucosal immunity to ricin.

Authors:  Lori M Neal; Joanne O'Hara; Robert N Brey; Nicholas J Mantis
Journal:  Infect Immun       Date:  2009-10-26       Impact factor: 3.441

10.  Enhancement of toxin- and virus-neutralizing capacity of single-domain antibody fragments by N-glycosylation.

Authors:  M M Harmsen; C B van Solt; H P D Fijten
Journal:  Appl Microbiol Biotechnol       Date:  2009-05-12       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.